MCID: PPL018
MIFTS: 50

Papillary Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Adenocarcinoma

MalaCards integrated aliases for Papillary Adenocarcinoma:

Name: Papillary Adenocarcinoma 12 15 74
Infiltrating and Papillary Adenocarcinoma 12
Infiltrating Papillary Adenocarcinoma 12
Adenocarcinoma, Papillary 45
Adenocarcinoma Papillary 56

Classifications:



External Ids:

Disease Ontology 12 DOID:3112
MeSH 45 D000231
NCIt 51 C2853 C7438
SNOMED-CT 69 4797003 64524002

Summaries for Papillary Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures and exhibit compressive, destructive growth that replaces the normal tissue.

MalaCards based summary : Papillary Adenocarcinoma, also known as infiltrating and papillary adenocarcinoma, is related to gastric papillary adenocarcinoma and aggressive digital papillary adenocarcinoma. An important gene associated with Papillary Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Letrozole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include thyroid, cervix and ovary, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Wikipedia : 77 Papillary adenocarcinoma is a histological form of lung cancer that is diagnosed when the malignant... more...

Related Diseases for Papillary Adenocarcinoma

Diseases related to Papillary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 354)
# Related Disease Score Top Affiliating Genes
1 gastric papillary adenocarcinoma 34.1 ERBB2 TP53
2 aggressive digital papillary adenocarcinoma 34.0 CEACAM5 MUC1
3 eccrine papillary adenocarcinoma 34.0 KRT7 PGR
4 renal cell carcinoma, papillary, 1 31.9 ERBB2 KRT7 TP53
5 adenocarcinoma 31.1 CDH1 ERBB2 MUC1 TP53
6 papillary serous adenocarcinoma 31.1 BRCA1 KRT7 NKX2-1 PGR TP53
7 papillary adenoma 30.4 KRT7 NKX2-1
8 rete testis adenocarcinoma 30.3 CEACAM5 NKX2-1
9 pulmonary sclerosing hemangioma 30.2 KRT7 NKX2-1
10 alveoli adenoma 30.2 KRT7 NKX2-1
11 endometrial mucinous adenocarcinoma 30.1 MUC1 PGR
12 cervical adenocarcinoma 30.1 ERBB2 KRT7 PGR TP53
13 fallopian tube adenocarcinoma 30.0 BRCA1 BRCA2 ERBB2
14 pseudo-meigs syndrome 30.0 CDH1 MUC16
15 epithelial-myoepithelial carcinoma 30.0 KRT7 TP53
16 thymus adenocarcinoma 29.8 CEACAM5 KRT7
17 cystadenoma 29.8 KRT7 MUC1 PGR
18 mucinous adenocarcinoma 29.8 KRT7 MUC1 NKX2-1
19 bronchiolo-alveolar adenocarcinoma 29.7 CDH1 KRT7 NKX2-1
20 squamous cell carcinoma 29.7 CDH1 ERBB2 MUC1 TP53
21 cystic teratoma 29.5 KRT7 NKX2-1 TP53
22 teratoma 29.5 KRT7 NKX2-1 TP53
23 sclerosing hemangioma 29.5 KRT7 MUC1 NKX2-1 PGR
24 cholecystitis 29.3 CDH1 MUC1 TP53
25 carcinosarcoma 29.1 ERBB2 KRT7 MUC1 PGR TP53
26 sweat gland cancer 29.1 ERBB2 KRT7 PGR TP53
27 mesothelioma, malignant 29.1 CEACAM5 KRT7 MUC1 MUC16 NKX2-1
28 endometrial adenocarcinoma 29.1 ERBB2 KRT7 PGR TP53
29 transitional cell carcinoma 29.1 CDH1 ERBB2 KRT7 TP53
30 papillary carcinoma 28.6 CDH1 ERBB2 KRT7 MUC1 NKX2-1 PGR
31 gastric adenocarcinoma 28.1 CDH1 CEACAM5 ERBB2 KRT7 MUC1 TP53
32 cystadenocarcinoma 28.0 CEACAM5 ERBB2 KRT7 MUC1 MUC16 PGR
33 lung cancer susceptibility 3 27.8 CDH1 CEACAM5 ERBB2 KRT7 MUC1 NKX2-1
34 ovarian cancer 27.5 BRCA1 BRCA2 CDH1 ERBB2 KRT7 MUC1
35 lung papillary adenocarcinoma 12.5
36 fallopian tube papillary adenocarcinoma 12.3
37 peritoneal serous papillary adenocarcinoma 12.3
38 papillary thymic adenocarcinoma 11.3
39 nasopharyngeal carcinoma 3 11.2
40 papillary follicular thyroid adenocarcinoma 11.1
41 breast-ovarian cancer, familial 1 10.4 BRCA1 BRCA2
42 breast reconstruction 10.4 BRCA1 BRCA2
43 premature menopause 10.4 BRCA1 BRCA2
44 fallopian tube disease 10.4 BRCA1 BRCA2
45 adenomyoma 10.4 KRT7 MUC1
46 parachordoma 10.4 KRT7 MUC1
47 colloid carcinoma of the pancreas 10.4 BRCA2 MUC1
48 spindle cell sarcoma 10.4 KRT7 MUC1
49 mucinous tubular and spindle renal cell carcinoma 10.4 KRT7 MUC1
50 secretory meningioma 10.4 KRT7 MUC1

Graphical network of the top 20 diseases related to Papillary Adenocarcinoma:



Diseases related to Papillary Adenocarcinoma

Symptoms & Phenotypes for Papillary Adenocarcinoma

GenomeRNAi Phenotypes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.23 BRCA1 BRCA2 CDH1 ERBB2 KRT7 NKX2-1

MGI Mouse Phenotypes related to Papillary Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.06 BRCA1 BRCA2 CDH1 ERBB2 KRT7 NKX2-1
2 digestive/alimentary MP:0005381 9.91 BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 TP53
3 endocrine/exocrine gland MP:0005379 9.91 BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 PGR
4 embryo MP:0005380 9.88 BRCA1 BRCA2 CDH1 ERBB2 PGR TP53
5 integument MP:0010771 9.8 BRCA1 BRCA2 CDH1 ERBB2 PGR TP53
6 neoplasm MP:0002006 9.7 BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 PGR
7 limbs/digits/tail MP:0005371 9.65 BRCA1 BRCA2 ERBB2 PGR TP53
8 normal MP:0002873 9.5 BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 PGR
9 reproductive system MP:0005389 9.17 BRCA1 BRCA2 CDH1 ERBB2 NKX2-1 PGR

Drugs & Therapeutics for Papillary Adenocarcinoma

Drugs for Papillary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
2
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
3
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 5284616 6436030
4
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
5
Bevacizumab Approved, Investigational Phase 2 216974-75-3
6
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
7
nivolumab Approved Phase 2 946414-94-4
8
Ipilimumab Approved Phase 2 477202-00-9
9
Gemcitabine Approved Phase 2 95058-81-4 60750
10
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
11
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
12
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
13
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
14
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
15
Atrasentan Investigational Phase 2 173937-91-2, 195733-43-8 159594
16
Doxil Approved June 1999 Phase 2 31703
17 Anti-Bacterial Agents Phase 2
18 Aromatase Inhibitors Phase 2
19 Estrogen Receptor Antagonists Phase 2
20 Estrogen Antagonists Phase 2
21 Hormones Phase 2
22 Anti-Infective Agents Phase 2
23 Immunosuppressive Agents Phase 2
24 Steroid Synthesis Inhibitors Phase 2
25 Hormone Antagonists Phase 2
26 Immunologic Factors Phase 2
27 Antibiotics, Antitubercular Phase 2
28 Estrogens Phase 2
29 Antifungal Agents Phase 2
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
31 Mitogens Phase 2
32 Antibodies Phase 2
33 Endothelial Growth Factors Phase 2
34 Liver Extracts Phase 2
35 Immunoglobulin G Phase 2
36 Antibodies, Monoclonal Phase 2
37 Antineoplastic Agents, Immunological Phase 2
38 Angiogenesis Modulating Agents Phase 2
39 Immunoglobulins Phase 2
40 Angiogenesis Inhibitors Phase 2
41 Antiviral Agents Phase 2
42 Antimetabolites Phase 2
43 Antimetabolites, Antineoplastic Phase 2
44 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
45 Protein Kinase Inhibitors Phase 1, Phase 2
46 Endothelin A Receptor Antagonists Phase 2
47 taxane Phase 2
48 Endothelin Receptor Antagonists Phase 2
49 Topoisomerase Inhibitors Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
2 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
3 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
4 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
5 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
6 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2 Cediranib Maleate;Olaparib
7 Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma Terminated NCT00653328 Phase 2 atrasentan hydrochloride;doxil
8 Research Study in Patients With Advanced Ovarian Epithelial Cancer Withdrawn NCT00053235

Search NIH Clinical Center for Papillary Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, papillary

Genetic Tests for Papillary Adenocarcinoma

Anatomical Context for Papillary Adenocarcinoma

MalaCards organs/tissues related to Papillary Adenocarcinoma:

42
Thyroid, Cervix, Ovary, Lung, Pancreas, Kidney, Testis

Publications for Papillary Adenocarcinoma

Articles related to Papillary Adenocarcinoma:

(show top 50) (show all 380)
# Title Authors Year
1
Genetic analysis of digital papillary adenocarcinoma. ( 31025737 )
2019
2
Thymic papillary adenocarcinoma coexisting with type A thymoma: A case report. ( 30959362 )
2019
3
Aggressive Digital Papillary Adenocarcinoma at Atypical Site. ( 30792586 )
2019
4
Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma. ( 30472730 )
2019
5
Low-grade papillary adenocarcinoma of nasopharynx. Case report and review of the literature. ( 30075860 )
2019
6
Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. ( 30039320 )
2019
7
Endoscopic submucosal dissection of papillary adenocarcinoma of stomach; protocol for a systematic review and meta-analysis. ( 30593208 )
2018
8
Biphasic low-grade nasopharyngeal papillary adenocarcinoma: a case report and literature review. ( 30323715 )
2018
9
Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma. ( 29995295 )
2018
10
Nasopharyngeal Papillary Adenocarcinoma as a Second Head and Neck Malignancy. ( 29923095 )
2018
11
Highly variable clinical feature and course of aggressive digital papillary adenocarcinoma. ( 29194742 )
2018
12
The So-Called Aggressive Digital Papillary Adenocarcinoma Is Epithelial-Myoepithelial Carcinoma. ( 29384814 )
2018
13
Aggressive Digital Papillary Adenocarcinoma: Population-Based Analysis of Incidence, Demographics, Treatment, and Outcomes. ( 29578881 )
2018
14
Masson's Tumor Masquerading as a Papillary Adenocarcinoma on Fine Needle Aspiration Cytology: A Case Report. ( 28272657 )
2018
15
Pulmonary papillary adenocarcinoma with Aspergillus versicolor infection in a dog. ( 29234587 )
2018
16
Lymphovascular invasion and lymph node metastasis rates in papillary adenocarcinoma of the stomach: implications for endoscopic resection. ( 29280035 )
2018
17
Endonasal endoscopic nasopharyngectomy for the treatment of nasopharyngeal papillary adenocarcinoma: Report of a rare case. ( 29287881 )
2018
18
Clinicopathologic Characteristics of Thyroid-like Low-grade Nasopharyngeal Papillary Adenocarcinoma: A Case Report. ( 29494399 )
2018
19
Papillary Adenocarcinoma in a Gastric Duplication Cyst. ( 29563742 )
2018
20
Cutaneous papillary adenocarcinoma in situ. ( 28164358 )
2017
21
Response to: Cutaneous papillary adenocarcinoma in situ. ( 28299799 )
2017
22
Mohs Micrographic Surgery as a Digit-Sparing Treatment for Aggressive Digital Papillary Adenocarcinoma. ( 28291063 )
2017
23
Aggressive Digital Papillary Adenocarcinoma of the Hand Presenting as a Felon. ( 28421154 )
2017
24
Aggressive digital papillary adenocarcinoma: A clinicopathological study of 19 cases. ( 28495496 )
2017
25
Aggressive digital papillary adenocarcinoma: treatment with Mohs micrographic surgery and an update of the literature. ( 28832985 )
2017
26
Clinicopathological and molecular stability and methylation analyses of gastric papillary adenocarcinoma. ( 28830689 )
2017
27
Papillary adenocarcinoma with tentacular processes (with video). ( 27302875 )
2017
28
Clinicopathological Features of Low-Grade Thyroid-like Nasopharyngeal Papillary Adenocarcinoma. ( 27384157 )
2017
29
Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: is it really safe? ( 28271420 )
2017
30
Primary papillary adenocarcinoma of the lung: Report of two cases. ( 28474664 )
2017
31
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with squamous differentiation: a novel histological finding. ( 28601658 )
2017
32
Cronkhite-Canada Syndrome with a Major Duodenal Papillary Adenocarcinoma. ( 28924129 )
2017
33
An Alpha Fetoprotein Producing Gastric Tumor with Yolk Sac, Hepatoid and Papillary Adenocarcinoma Components. ( 29207718 )
2017
34
Nasopharyngeal papillary adenocarcinoma. ( 29236265 )
2017
35
Primary thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: A case report and literature review. ( 29381996 )
2017
36
Malignant transformation of alveolar adenoma to papillary adenocarcinoma: a case report. ( 27162700 )
2016
37
Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. ( 27098633 )
2016
38
Papillary adnexal neoplasm (aggressive digital papillary adenocarcinoma) on the ankle of a 15-year-old girl: case report and review of literature from a pediatric perspective. ( 27535353 )
2016
39
Aggressive Digital Papillary Adenocarcinoma With Multiple Organ Metastases: A Case Report and Review of the Literature. ( 27870729 )
2016
40
"Apocrine Hidrocystoma and Cystadenoma"-like Tumor of the Digits or Toes: A Potential Diagnostic Pitfall of Digital Papillary Adenocarcinoma. ( 26523544 )
2016
41
Metastatic Papillary Adenocarcinoma in a 22-Year-Old: Is Her History of Mayer-Rokitansky-Küster-Hauser Syndrome Causative or Incidental? ( 27987200 )
2016
42
Spreading patterns, prognostic factors and treatment outcomes of nasopharyngeal papillary adenocarcinoma and salivary gland-type carcinomas. ( 26118586 )
2016
43
Villoglandular papillary adenocarcinoma of the uterine cervix: A report of 4 cases and a review of the literature. ( 26870293 )
2016
44
A retrospective review of 11 cases of villoglandular papillary adenocarcinoma of the uterine cervix and a review of the literature. ( 26998142 )
2016
45
Papillary adenocarcinoma of the renal pelvis with renal calculus: A rare case report. ( 27123287 )
2016
46
Low-grade nasopharyngeal papillary adenocarcinoma: a case report and review of the literature. ( 27274289 )
2016
47
Treatment of endolymphatic sac tumour (Papillary adenocarcinoma) of the temporal bone. ( 27330425 )
2016
48
Aggressive papillary adenocarcinoma on atypical localization: A unique case report. ( 27428196 )
2016
49
Low-grade papillary adenocarcinoma of nasopharynx with expression of thyroid transcription factor-1: Case report and review of literature. ( 27721286 )
2016
50
An unexpected digital papillary adenocarcinoma of the thumb. ( 27990456 )
2016

Variations for Papillary Adenocarcinoma

Expression for Papillary Adenocarcinoma

Search GEO for disease gene expression data for Papillary Adenocarcinoma.

Pathways for Papillary Adenocarcinoma

Pathways related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 BRCA2 CDH1 ERBB2 TP53
2 12.52 BRCA2 CDH1 ERBB2 TP53
3
Show member pathways
12.22 CDH1 ERBB2 MUC1 TP53
4
Show member pathways
12.15 BRCA1 BRCA2 CDH1 ERBB2 TP53
5
Show member pathways
11.77 BRCA1 BRCA2 CDH1 ERBB2 PGR TP53
6 11.72 CDH1 CEACAM5 MUC1
7
Show member pathways
11.5 BRCA1 BRCA2 TP53
8 11.44 BRCA1 BRCA2 CDH1 TP53
9 11.41 CDH1 ERBB2 TP53
10 11.36 BRCA1 ERBB2 TP53
11 11.29 BRCA1 BRCA2 TP53
12 11.25 BRCA1 ERBB2 TP53
13 11.05 CDH1 ERBB2
14 11.04 BRCA1 TP53
15 11 BRCA1 TP53
16 10.76 BRCA1 TP53

GO Terms for Papillary Adenocarcinoma

Cellular components related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.65 BRCA1 BRCA2 CDH1 NKX2-1 TP53
2 positive regulation of gene expression GO:0010628 9.62 BRCA1 ERBB2 NKX2-1 TP53
3 oligodendrocyte differentiation GO:0048709 9.49 ERBB2 NKX2-1
4 response to gamma radiation GO:0010332 9.48 BRCA2 TP53
5 cell aging GO:0007569 9.46 BRCA2 TP53
6 pituitary gland development GO:0021983 9.43 CDH1 NKX2-1
7 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.4 BRCA2 TP53
8 positive regulation of cell cycle arrest GO:0071158 9.37 BRCA1 TP53
9 cellular response to indole-3-methanol GO:0071681 9.16 BRCA1 CDH1
10 chordate embryonic development GO:0043009 8.96 BRCA1 BRCA2
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.92 BRCA1 BRCA2 MUC1 TP53

Molecular functions related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.46 MUC1 NKX2-1 PGR TP53
2 enzyme binding GO:0019899 9.26 BRCA1 NKX2-1 PGR TP53
3 identical protein binding GO:0042802 9.17 BRCA1 BRCA2 CDH1 CEACAM5 ERBB2 PGR

Sources for Papillary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....